Bibliographical noteFunding Information:
A. Khoruts has received research funding from Crestovo, a start-up company working to commercialize FMT. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.
- Clostridium difficile infection
- fecal microbiota transplantation (FMT)
- microbial community
- microbiota therapeutics